• LAST PRICE
    0.5399
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.5401/ 15
  • Ask / Lots
    0.5474/ 5
  • Open / Previous Close
    0.0000 / 0.5399
  • Day Range
    ---
  • 52 Week Range
    Low 0.5020
    High 2.1200
  • Volume
    1,366
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeBXRX
Data delayed at least 15 minutes.

Oct 5, 2021

7:00AM ET on Tuesday Oct 05, 2021 by GlobeNewswire

Oct 1, 2021

4:17PM ET on Friday Oct 01, 2021 by GlobeNewswire
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBXRX
Baudax Bio Inc
45.6M
-1.4x
---
United StatesMTP
Midatech Pharma PLC
34.5M
-2.0x
---
United StatesMRZM
Marizyme Inc
47.0M
-4.4x
---
United StatesFWP
Forward Pharma A/S
46.3M
-8.7x
---
United StatesRVPH
Reviva Pharmaceuticals Holdings, Inc.
46.3M
-14.2x
---
United StatesIKT
Inhibikase Therapeutics Inc
48.3M
-2.7x
---
As of 2021-10-20

Company Information

Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO (meloxicam) injection. ANJESO is a preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory, and antipyretic activities. The injectable form of IV meloxicam, which utilizes NanoCrystal technology, increases overall drug solubility that provides a faster onset of action of meloxicam and provides a rapid treatment of acute pain. Its product pipeline includes Neuromuscular blocking agents (NMBAs), which are used as muscle paralyzing agents to facilitate intubation and surgery. The Company is developing intermediate-acting NMBA, BX1000, an ultrashort-acting NMBA, BX2000, and a reversal agent specific to its NMBAs. Its other products include Dex-IN, which is a selective alpha-2 adrenergic agonist that has sedative, analgesic, and anxiolytic properties.

Contact Information

Headquarters
490 Lapp RdMALVERN, PA, United States 19355-1212
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Alfred Altomari
President, Chief Executive Officer, Director
Geraldine Henwood
Chief Financial Officer
Richard Casten
Independent Director
William Ashton
Independent Director
Arnold Baskies

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$45.6M
Revenue (TTM)
$543.0K
Shares Outstanding
84.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.40
Book Value
$-0.30
P/E Ratio
-1.4x
Price/Sales (TTM)
83.9
Price/Cash Flow (TTM)
---
Operating Margin
-6,787.66%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.